单细胞多组学揭示KMT2A重排白血病中可塑性增加、耐药群体及干细胞样原始细胞
该研究对KMT2A重排婴儿急性淋巴细胞白血病(ALL)患者不同年龄的白血病细胞及正常造血细胞进行单细胞多组学分析,发现小于6月龄患者白血病细胞谱系可塑性显著增加,最未成熟原始细胞中类固醇反应通路下调,并鉴定出含白血病原始细胞的造血干/祖细胞样(HSPC样)群体,该群体与细胞毒性淋巴细胞形成免疫抑制信号回路。研究还发现初诊B-ALL时即存在淋系-髓系预致敏祖细胞和髓系原始细胞,并在2例发生谱系转换的患者中追踪到克隆演变为急性髓系白血病(AML)。
要点
- 小于6月龄KMT2A-r ALL患者白血病细胞谱系可塑性显著增加。
- 年轻患者最未成熟原始细胞中类固醇反应通路下调。
- 年轻患者血中含HSPC样群体,与细胞毒性淋巴细胞形成免疫抑制信号回路。
核心结论
- KMT2A-r ALL中年龄相关差异包括谱系可塑性增加、类固醇反应通路下调和HSPC样免疫抑制回路,可解释年轻患者白血病逃逸化疗和免疫控制的能力。
- 初诊B-ALL即存在淋系-髓系预致敏祖细胞和髓系原始细胞,谱系转换患者中这些克隆可演变为AML。
研究设计与样本
- 对来自不同年龄患者的KMT2A-r白血病细胞及正常造血细胞进行单细胞多组学分析。
主要发现
- 小于6月龄患者白血病细胞谱系可塑性显著增加。
- 年轻患者最未成熟原始细胞中类固醇反应通路下调。
- 年轻患者血中鉴定出含白血病原始细胞的HSPC样群体,与细胞毒性淋巴细胞形成免疫抑制信号回路。
- 初诊B-ALL时即存在淋系-髓系预致敏祖细胞和髓系原始细胞。
- 在2例发生谱系转换的患者中追踪到白血病克隆演变为AML。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KMT2A-rearranged (KMT2A-r) infant acute lymphoblastic leukemia (ALL) is a devastating malignancy with a dismal outcome, and younger age at diagnosis is associated with increased risk of relapse. To discover age-specific differences and critical drivers that mediate poor outcome in KMT2A-r ALL, we subjected KMT2A-r leukemias and normal hematopoietic cells from patients of different ages to single-cell multiomics analyses. We uncovered the following critical new insights: leukemia cells from patients <6 months have significantly increased lineage plasticity. Steroid response pathways are downregulated in the most immature blasts from younger patients. We identify a hematopoietic stem and progenitor-like (HSPC-like) population in the blood of younger patients that contains leukemic blasts and form an immunosuppressive signaling circuit with cytotoxic lymphocytes. These observations offer a compelling explanation for the ability of leukemias in young patients to evade chemotherapy and immune-mediated control. Our analysis also revealed preexisting lymphomyeloid primed progenitors and myeloid blasts at initial diagnosis of B-ALL. Tracking of leukemic clones in 2 patients whose leukemia underwent a lineage switch documented the evolution of such clones into frank acute myeloid leukemia (AML). These findings provide critical insights into KMT2A-r ALL and have clinical implications for molecularly targeted and immunotherapy approaches. Beyond infant ALL, our study demonstrates the power of single-cell multiomics to detect tumor intrinsic and extrinsic factors affecting rare but critical subpopulations within a malignant population that ultimately determines patient outcome.
引用
- Chen C, Yu W, Alikarami F, et al. Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia. Blood. 2022. PMID: 34864916. doi:10.1182/blood.2021013442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。